ROBERT ATMAR to Middle Aged
This is a "connection" page, showing publications ROBERT ATMAR has written about Middle Aged.
Connection Strength
1.023
-
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine. J Infect Dis. 2025 Oct 15; 232(4):971-981.
Score: 0.056
-
Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen-Blocking Antibody Levels. J Infect Dis. 2024 Dec 16; 230(6):1376-1379.
Score: 0.053
-
A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies. J Infect Dis. 2024 May 15; 229(5):1402-1407.
Score: 0.051
-
Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022 03 17; 386(11):1046-1057.
Score: 0.043
-
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season. MMWR Recomm Rep. 2020 08 21; 69(8):1-24.
Score: 0.039
-
Comparison of Microneutralization and Histo-Blood Group Antigen-Blocking Assays for Functional Norovirus Antibody Detection. J Infect Dis. 2020 02 18; 221(5):739-743.
Score: 0.038
-
A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
Score: 0.037
-
Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination. J Infect Dis. 2019 07 19; 220(4):603-614.
Score: 0.036
-
An Exploratory Study of the Salivary Immunoglobulin A Responses to 1 Dose of a Norovirus Virus-Like Particle Candidate Vaccine in Healthy Adults. J Infect Dis. 2019 01 09; 219(3):410-414.
Score: 0.035
-
Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial. J Infect Dis. 2016 Sep 15; 214(6):845-53.
Score: 0.029
-
Serological Correlates of Protection against a GII.4 Norovirus. Clin Vaccine Immunol. 2015 Aug; 22(8):923-9.
Score: 0.027
-
Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis. 2014 Apr 01; 209(7):1016-22.
Score: 0.025
-
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011 Dec 08; 365(23):2178-87.
Score: 0.021
-
Picornavirus, the most common respiratory virus causing infection among patients of all ages hospitalized with acute respiratory illness. J Clin Microbiol. 2012 Feb; 50(2):506-8.
Score: 0.021
-
Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine. 2011 Oct 19; 29(45):8066-72.
Score: 0.021
-
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 02 04; 384(5):403-416.
Score: 0.020
-
Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis. 2010 Oct 15; 202(8):1212-8.
Score: 0.020
-
Norwalk virus shedding after experimental human infection. Emerg Infect Dis. 2008 Oct; 14(10):1553-7.
Score: 0.017
-
Sequential outbreaks of infections by distinct Acinetobacter baumannii strains in a public teaching hospital in Houston, Texas. J Clin Microbiol. 2008 Jan; 46(1):198-205.
Score: 0.016
-
A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine. 2007 Jul 20; 25(29):5367-73.
Score: 0.016
-
The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults. Vaccine. 2026 Apr 02; 77:128358.
Score: 0.014
-
Using Machine Learning Algorithms to Identify Key Predictors of Invasive Mold Infection Surveillance. J Infect Dis. 2025 Dec 20; 232(6):e1033-e1042.
Score: 0.014
-
Clinical factors and diagnoses associated with inappropriate urine culture ordering in primary care. Infect Control Hosp Epidemiol. 2026 Jan; 47(1):80-87.
Score: 0.014
-
SARS-CoV-2 spike sequence-based distance as a marker of binding antibody response to COVID-19 vaccines. Vaccine. 2025 Oct 24; 65:127738.
Score: 0.014
-
Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect. 2005 May; 50(4):322-30.
Score: 0.014
-
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. 2025 02 05; 80(1):223-227.
Score: 0.013
-
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost. Nat Commun. 2025 Jan 17; 16(1):759.
Score: 0.013
-
Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59?. Vaccine. 2025 02 15; 47:126702.
Score: 0.013
-
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens. Vaccine. 2025 02 15; 47:126689.
Score: 0.013
-
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 06 14; 78(6):1757-1768.
Score: 0.013
-
Determining a urinary-specific antibiogram and risk factors of trimethoprim/sulfamethoxazole, ciprofloxacin and multidrug resistance among Enterobacterales in primary care. J Antimicrob Chemother. 2024 03 01; 79(3):559-563.
Score: 0.013
-
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022 09; 10(9):888-899.
Score: 0.011
-
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 12; 9(12):1365-1376.
Score: 0.011
-
'String Test' for Hypermucoviscous Klebsiella pneumoniae. Am J Med. 2021 10; 134(10):e520-e521.
Score: 0.010
-
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 03 04; 384(9):795-807.
Score: 0.010
-
Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 11 05; 383(19):1813-1826.
Score: 0.010
-
Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 Jul; 162(1):167-73.
Score: 0.010
-
Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recomm Rep. 2019 12 13; 68(4):1-14.
Score: 0.009
-
Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2019 07 19; 68(2):1-33.
Score: 0.009
-
Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.
Score: 0.009
-
Dialysis Catheter-related Bloodstream Infections in Patients Receiving Hemodialysis on an Emergency-only Basis: A Retrospective Cohort Analysis. Clin Infect Dis. 2019 03 05; 68(6):1011-1016.
Score: 0.009
-
Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial. Vaccine. 2017 08 24; 35(36):4730-4737.
Score: 0.008
-
Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades. J Virol. 2017 07 15; 91(14).
Score: 0.008
-
Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. Vaccine. 2016 Jan 20; 34(4):547-554.
Score: 0.007
-
In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infect Control Hosp Epidemiol. 2015 Nov; 36(11):1318-23.
Score: 0.007
-
Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46.
Score: 0.007
-
Host Transcriptional Response to Influenza and Other Acute Respiratory Viral Infections--A Prospective Cohort Study. PLoS Pathog. 2015 Jun; 11(6):e1004869.
Score: 0.007
-
Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine. Vaccine. 2015 Jan 15; 33(4):568-76.
Score: 0.007
-
Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
Score: 0.007
-
Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis. 2015 Mar 15; 211(6):870-8.
Score: 0.006
-
A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis. 2014 Dec 01; 210(11):1763-71.
Score: 0.006
-
Effects of infection and disease with Mycobacterium tuberculosis on serum antibody to glucan and arabinomannan: two surface polysaccharides of this pathogen. BMC Infect Dis. 2013 Jun 19; 13:276.
Score: 0.006
-
Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis. 2013 Mar 15; 207(6):974-81.
Score: 0.006
-
Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
Score: 0.006
-
Stem cell-derived human intestinal organoids as an infection model for rotaviruses. mBio. 2012; 3(4):e00159-12.
Score: 0.006
-
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med. 1991 Jan 15; 114(2):119-27.
Score: 0.005
-
Characterization of norovirus-associated traveler's diarrhea. Clin Infect Dis. 2010 Jul 15; 51(2):123-30.
Score: 0.005
-
Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2010 Jun; 125(6):1369-1378.e2.
Score: 0.005
-
Comprehensive analysis of a norovirus-associated gastroenteritis outbreak, from the environment to the consumer. J Clin Microbiol. 2010 Mar; 48(3):915-20.
Score: 0.005
-
Aichi virus, norovirus, astrovirus, enterovirus, and rotavirus involved in clinical cases from a French oyster-related gastroenteritis outbreak. J Clin Microbiol. 2008 Dec; 46(12):4011-7.
Score: 0.004
-
Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infect Dis. 2008 Jan 15; 8:4.
Score: 0.004
-
Inactivated influenza vaccination for people with spinal cord injury. Arch Phys Med Rehabil. 2004 Nov; 85(11):1886-9.
Score: 0.003
-
Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. J Allergy Clin Immunol. 2004 Apr; 113(4):717-24.
Score: 0.003
-
Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003 Oct 15; 168(8):968-75.
Score: 0.003
-
Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. FEMS Immunol Med Microbiol. 2003 Jun 10; 37(1):69-75.
Score: 0.003
-
Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002 May; 81(3):213-27.
Score: 0.003
-
Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med. 2001 Dec 01; 164(11):2114-9.
Score: 0.003
-
Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000 Jan 26; 283(4):499-505.
Score: 0.002
-
Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999 Oct 28; 341(18):1336-43.
Score: 0.002
-
Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine. 1999 Oct 14; 18(5-6):531-9.
Score: 0.002
-
Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors. Clin Infect Dis. 1998 Nov; 27(5):1231-7.
Score: 0.002
-
Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis. 1998 Jun; 26(6):1418-24.
Score: 0.002
-
Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. 1997 Aug; 25(2):230-9.
Score: 0.002
-
Life-threatening Pseudomonas aeruginosa infections in patients with human immunodeficiency virus infection. Clin Infect Dis. 1992 Feb; 14(2):403-11.
Score: 0.001
-
B-cell activation and differentiation by HIV-1 antigens among volunteers vaccinated with VaxSyn HIV-1. J Acquir Immune Defic Syndr (1988). 1992; 5(7):719-25.
Score: 0.001